At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts

▤ Summary

The article covers the first public hearing on the FDA’s Commissioner’s National Priority Voucher pilot program. Drugmakers such as Johnson & Johnson, Merck, and Partner Therapeutics voiced support for the program and described faster review timelines and clearer collaboration with the agency. Critics warned that the voucher process could become politicized, lack transparency, and strain FDA resources. Patient advocates pushed the agency to use the program for breakthrough therapies in rare and serious diseases. The public can still submit comments through June 29, and those comments will shape the program’s future.

▦ Linked Companies